Superluminal Medicines closed an oversubscribed $60 million Series B to advance its obesity program into clinical trials and expand its GPCR drug pipeline.
- Amount
- $60M
- Stage
- Series B
- Announced
- 3 September 2026
- Lead
- BVF Partners, L.P.
- Other investors
- Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, Gaingels
- Use of funds
- Initiating Phase 1 trial for rare genetic obesity by end of 2026, advancing additional pipeline programs and expanding GPCR-targeted portfolio
- Checked
- Announced by the company